ICAD icon

iCAD Inc

3.22 USD
+0.10
3.21%
Updated Apr 23, 1:20 PM EDT
1 day
3.21%
5 days
1.26%
1 month
41.23%
3 months
36.44%
6 months
84.00%
Year to date
61.81%
1 year
106.41%
5 years
-70.51%
10 years
-69.39%
 

About: icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Employees: 66

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

21% more call options, than puts

Call options by funds: $57K | Put options by funds: $47K

10% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 10

9% more capital invested

Capital invested by funds: $8.15M [Q3] → $8.91M (+$765K) [Q4]

1.25% less ownership

Funds ownership: 19.6% [Q3] → 18.35% (-1.25%) [Q4]

4% less funds holding

Funds holding: 47 [Q3] → 45 (-2) [Q4]

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Research analyst outlook

We haven’t received any recent analyst ratings for ICAD.

Financial journalist opinion

Based on 4 articles about ICAD published over the past 30 days

Neutral
Business Wire
6 days ago
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
Neutral
PRNewsWire
6 days ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of iCAD, Inc. - ICAD
NEW YORK , April 16, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating iCAD, Inc. (NASDAQ: ICAD ), relating to the proposed merger with RadNet, Inc. Under the terms of the agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock held at the closing of the merger.
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of iCAD, Inc. - ICAD
Neutral
Business Wire
1 week ago
ICAD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iCad, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iCAD, Inc. (NASDAQ: ICAD) to RadNet, Inc. for 0.0677 shares of RadNet common stock for each share of iCAD common stock is fair to iCAD shareholders. Halper Sadeh encourages iCAD shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation c.
ICAD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iCad, Inc. Is Fair to Shareholders
Neutral
GlobeNewsWire
2 weeks ago
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer
NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD.
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer
Neutral
Seeking Alpha
1 month ago
iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Rosalyn Christian - IR Dana Brown - President, CEO and Chairman Eric Lonnqvist - CFO Conference Call Participants Marie Thibault - BTIG Per Ostlund - Craig-Hallam Capital Yale Jen - Laidlaw & Company Gene Mannheimer - Freedom Capital Markets Operator Greetings. Welcome to the iCAD Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call.
iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024
NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024.
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024
Neutral
GlobeNewsWire
1 month ago
iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America
NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare providers worldwide utilizing RamSoft's solutions, this collaboration brings iCAD's ProFound AI® Breast Health Suite directly into imaging centers, enhancing workflow efficiency, increasing diagnostic confidence, and improving patient care, beginning within the platforms they already use.
iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America
Neutral
GlobeNewsWire
1 month ago
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025
NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD's ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists with an AI-powered pathway from screening to diagnosis.
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025
Neutral
GlobeNewsWire
2 months ago
iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025
NASHUA, N.H., Feb. 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company's advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, 2025, in Vienna, Austria.
iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025
Neutral
GlobeNewsWire
2 months ago
iCAD Pre-Announces Estimated Q4 2024 Revenue
iCAD to Participate in the BTIG at Snowbird: 12 th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
iCAD Pre-Announces Estimated Q4 2024 Revenue
Charts implemented using Lightweight Charts™